Article Data

  • Views 3552
  • Dowloads 334

Editorials

Open Access

Ibuprofen safety at the golden anniversary. A commentary and recent developments

  • Giustino Varrassi1
  • Joseph V. Pergolizzi2

1Paolo Procacci Foundation, Via Tacito 7, 00193, Roma, Italy

2NEMA Research, Inc., Naples, Florida, United States of America

DOI: 10.22514/sv.2020.16.0097 Vol.17,Issue 2,March 2021 pp.1-3

Published: 08 March 2021

*Corresponding Author(s): Giustino Varrassi E-mail: giuvarr@gmail.com

Abstract

Ibuprofen is a long lasting non-steroidal anti-inflammatory drugs (NSAIDs) and still represents one of the most diffused analgesics around the world. It has an interesting story started over 50 years ago. In this short comment to an already published paper, the authors try to focus some specific important point. On top, they illustrate the recent, confusing and fake assertion on the potentially dangerous influence that ibuprofen could have, increasing the risk of Coronavirus infection. This is also better illustrated in a previously published paper, where the readers could find more clear responses to eventual doubts.

Keywords

NSAIDs; Ibuprofen; COVID-19; Side effects

Cite and Share

Giustino Varrassi,Joseph V. Pergolizzi. Ibuprofen safety at the golden anniversary. A commentary and recent developments. Signa Vitae. 2021. 17(2);1-3.

References

[1] Available at: https://www.bbc.com/news/uk-england-nottinghamshire-47073913 (Accessed: 30 October, 2020).

[2] ANSM. Anti-inflammatoires non steroıdiens (AINS) et complications infectieuses graves-Point d’Information. Agence nationale de securite du medicament et des produits de sante. 2019. Available at: https://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Anti-inflammatoires-non-steroidiens-AINS-et-complications-infectieuses-graves-Point-d-Information (Accessed: 30 October, 2020).

[3] Taylor N. France’s ANSM warns about NSAIDs following safety review. Regulatory Affairs Professionals. EU Regulatory Roundup. 2019. Available at: https://www.raps.org/news-and-articles/news-articles/2019/4/eu-regulatory-roundup-frances-ansm-warns-about-n (Accessed: 30 October, 2020).

[4] Varrassi G, Pergolizzi JV, Dowling P, Paladini A. Ibuprofen safety at the golden anniversary: Are all NSAIDs the same? A narrative review. Advanced Therapeutics. 2019; 37: 61-82.

[5] Varrassi G, Yeam CT, Rekatsina M, Pergolizzi JV, Zis P, Paladini A. The expanding role of the COX inhibitor/opioid receptor agonist combination in the management of pain. Drugs. 2020; 80: 1443-1453.

[6] Moore A, Crossley A, Ng B, Phillips L, Sancak O, Rainsford KD. Use of multicriteria decision analysis for assessing the benefit and risk of over-the-counter-analgesics. Journal of Pharmacy and Pharmacology. 2017; 69: 1364-73.

[7] Kellstein DE, Waksman JA, Furey SA, Binstok G, Cooper SA. The safety profile of nonprescription ibuprofen in multiple-dose use: A meta-analysis. The Journal of Clinical Pharmacology. 1999; 39: 520-32.

[8] Moore N. Forty years of ibuprofen use. International Journal of Clinical Practice. 2003; 135: 28-31.

[9] Moore RA, Wiffen PJ, Derry S, Maguire T, Roy YM, Tyrrell L. Non-prescription (OTC) oral analgesics for acute pain-an overview of Cochrane reviews. Cochrane Database of Systematic Reviews. 2015; 11: CD010794.

[10] Available at: https://www.lefigaro.fr/sciences/coronavirus-alerte-sur-l-ibuprofene-et-autres-anti-inflammatoires-2020031 (Accessed: 30 October, 2020).

[11] Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respiratory Medicine. 2020; 8: e21.

[12] Varrassi G. Warning against the use of anti-inflammatory medicines to cure COVID-19: Building castles in the air. Advances in Therapy. 2020; 37: 1705-1707.

[13] Available at: https://www.theguardian.com/society/2020/apr/29/more-cases-of-rare-syndrome-in-children-reported-globally (Accessed: 30 October, 2020).

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 1.0 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time

Conferences

Top